Good news – “Ivermectin is one of the world’s safest, cheapest and most widely available drugs,” explained Dr. Kory, President of the FLCCC Alliance. “The studies we presented to the NIH revealed high levels of statistical significance showing large magnitude benefit in transmission rates, need for hospitalization, and death. What’s more, the totality of trials data supporting ivermectin is without precedent.”
NOTE TO MEMBERS OF PARLIAMENT IN SOUTH AFRICA
South Africa must follow the same path as USA and give medical doctors the opportunity to assist and help the ill people. All citizens must be treated with respect and humanity – especially by members of parliament members or others that make the rules (get away with people like Soros and others – OSF.SA and Cato Institute).
It is time that all the past corruption in 27 years, in all governments need urgent attention and be fully investigated by the public, not those that making the rules. Members of Parliament can not investigate themselves. All those money must be given back to the tax payers.
Furthermore, South Africa need to stop their racism against the white minority in South Africa, the Black Economic Empowerment and all related legislations need to be stopped immediately and repealed – that is unhuman and violation of human rights. We are all sick and tired of corruption, racism and crime in South Africa, even during this period of Covid-19. There was no humanity at all to close the doors of businesses and are even worse if people can not live without food and medication if they are sick and hunger because of corruption, crime and racism.
BACK AT THE GOOD NEWS – IVERMECTIN – WELL DONE TO ALL THE MEDICAL DOCTORS
BETHESDA, Maryland, January 19, 2021 (LifeSiteNews)
Following the diligent efforts of physicians associated with a group called Front Line Covid-19 Critical Care Alliance (FLCCC), the National Institutes of Health (NIH) has upgraded their recommendation for the “miraculous” drug ivermectin, making it an option for use in treating COVID-19 within the United States. The result comes one week after Dr. Paul Marik and Dr. Pierre Kory—founding members of the FLCCC, along with Dr. Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data before the NIH Treatment Guidelines Panel.
A press release from FLCCC explains the “new designation upgraded the status of ivermectin from ‘against’ [the drug’s use] to ‘neither for nor against,’ which is the same recommendation given to monoclonal antibodies and convalescent plasma, both widely used across the nation.”
“By no longer recommending against ivermectin use,” the statement said, “doctors should feel more open in prescribing ivermectin as another therapeutic option for the treatment of COVID-19. This may clear its path towards FDA [Food and Drug Administration] emergency use approval.”
In its January 14 updated statement regarding the use of ivermectin, NIH indicated they will continue to evaluate additional trials as they are released.
“We are encouraged that the NIH has moved off of its August 27 recommendation against the use of ivermectin for COVID-19,” continued Kory. “That recommendation was made just as the numerous compelling studies for ivermectin were starting to roll in. New studies are still coming in, and as they are received and reviewed, it is our hope that the NIH’s recommendation for the use of ivermectin will be the strongest recommendation for its use as possible.”
Last month Dr. Kory and his team testified before the U.S. Senate Homeland Security Committee in favor of authorizing ivermectin, a Nobel Prize–winning anti-parasitic agent, for early treatment of the novel coronavirus. In his impassioned presentation, Dr. Kory explained that ivermectin “basically obliterates transmission of this virus,” with “miraculous effectiveness.”
Ivermectin has been the subject of dozens of studies and anecdotal success stories since it was found to reduce COVID-19 in a laboratory in June 2020.
“I’ve been treating COVID pretty much every single day since the onset,” Kory said at the December hearing. “When I say ‘miracle’ I do not use that term lightly[.] … [T]hat is a scientific recommendation based on mountains of data that has emerged in the last three months.”
Such data emanates from places like India, the second most populated nation in the world, which embraced the treatment protocol advanced by FLCCC, and has watched its case and fatalities rate drop in “steep decline.” Though India has four times the population of the U.S., it has less than half of the coronavirus related deaths.
Other examples come from Bangladesh, Peru, Argentina, Brazil and several other South American countries, all of which have demonstrated the effectiveness of ivermectin.
Though FLCCC is encouraged by NIH’s movement to neutrality on this treatment, it asserts that their current stance remains “out of alignment with the known clinical, epidemiological, and observational data” which should compel them “to provide more specific guidance in support of the use of ivermectin in COVID-19,” and they provide a detailed analysis of the agency’s conclusions to that effect.
Ivermectin is Now a Treatment Option for Health Care Providers!
Jan 14, 2021 – One week after Dr. Paul Marik and Dr. Pierre Kory – founding members of the Front Line Covid-19 Critical Care Alliance (FLCCC) – along with Dr. Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data before the NIH Treatment Guidelines Panel, the NIH has upgraded their recommendation and now considers Ivermectin an option for use in COVID-19.
Their recommendation has now been upgraded to the same level as those for widely used monoclonal antibodies & convalescent plasma, which is a “neither for nor against” recommendation. The significance of this change is that the NIH has decided to no longer recommend against the use of ivermectin in the treatment of COVID-19 by the nation’s health care providers. A consequence of this change is that ivermectin has now been made a clear therapeutic option for patients.
The University of Liverpool’s Andrew Hill and others carried out a meta-analytical breakdown of 18 studies that found that ivermectin was associated with reduced inflammation and a faster elimination of Sars-Cov-2, the virus that causes Covid-19.
The only antiviral with some sort of approval globally to treat Covid-19 is Gilead Sciences’ remdesivir, which has shown some benefit in shortening hospital stays but no clear-cut effect on mortality or viral loads, a measure of how much virus circulates in a patient’s blood stream.
Ivermectin is not approved in the UK and is usually imported from France. But researchers were adamant that many of the studies that had been looked at had not been peer-reviewed and that meta-analyses, which look at many studies at once, could be prone to errors.
Dr. Andrew Hill’s Ivermectin meta-analysis, from University of Liverpool, England, supported by The Access to COVID-19 Tools (ACT) Accelerator.
Ivermectin, a Nobel Prize–winning anti-parasitic agent, has been the subject of dozens of studies and anecdotal success stories since it was found to reduce COVID-19 in a laboratory earlier this year.
Ivermectin is en word vir verskillende siektestoestande gebruik al vir dekades, nie net in Afrika gebruik. Dit het miljoene mense genees en voorkom dat hul verder rivierblindheid ontwikkel en parasitiese toestande geblok. Dis ‘n wondermiddel vir ‘n paar soorte siektestoestande. Dit word vir mense en diere gebruik.
Na verskeie mediese studies asook genesings wat aangeteken is, is bevind :
Ivermectin is een van die veiligste, goedkoopste en mees beskikbare middels ter wêreld, het dr. Kory, president van die FLCCC Alliansie, verduidelik. ‘Die studies wat ons aan die NIH voorgelê het, het hoë vlakke van statistiese beduidendheid getoon wat ‘n groot voordeel in transmissiesnelhede, hospitalisasiebehoeftes en sterftes toon. Wat meer is, die totale proefdata wat ivermektien ondersteun, is sonder weerga. ”
Na die onbaatsigtige en ywerige pogings van geneeshere verbonde aan ‘n groep genaamd ‘Front Line Covid-19 Critical Care Alliance (FLCCC)’, het die Nasional Instituut of Gesondheid van die Verenigde State van Amerika, hul aanbeveling vir die geneesmiddel ivermektien, wat vir verskillende siektestoestande behandel kan word, opgegradeer, wat dit ‘n opsie maak om te gebruik in die behandeling van COVID-19.
Die resultaat kom ‘n week nadat dr. Paul Marik en dr. Pierre Kory, beide stigterslede van die FLCCC, saam met dr. Andrew Hill, navorser en konsultant van die Wêreldgesondheids organisasie (WGO), hul gegewens voor die NIH Behandelingsriglyne-paneel aangebied het.
In ‘n persverklaring van FLCCC wat uitgereik is, word die “nuwe benaming die status van ivermektien opgradeer van ‘teen’ [die gebruik van die geneesmiddel] na ‘nie vir of teen’ nie, wat dieselfde aanbeveling is wat gegee word aan monoklonale teenliggaampies en herstelplasma, wat albei algemeen gebruik word.
“Deur nie meer aan te beveel om ivermektien te gebruik nie”, lui die verklaring, “behoort dokters met ‘n meer oop gemoed wees om ivermektien voor te skryf sonder om vervolg te word, as ‘n ander terapeutiese opsie vir die behandeling van COVID-19. Dit kan sy weg na die goedkeuring van die noodtoestand van die FDA [die voedsel- en geneesmiddel administrasie] skoonmaak. ”